{"id":"NCT03266588","sponsor":"Pfizer","briefTitle":"Open Label Safety Study in Acute Treatment of Migraine","officialTitle":"A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-08-30","primaryCompletion":"2019-07-15","completion":"2019-07-15","firstPosted":"2017-08-30","resultsPosted":"2020-07-02","lastUpdate":"2023-02-16"},"enrollment":3019,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, With or Without Aura"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":["BHV-3000"]}],"arms":[{"label":"Rimegepant","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).","primaryOutcome":{"measure":"Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period","timeFrame":"PRN (2-8) and PRN (9-14) groups: Up to 52 weeks; Scheduled EOD + PRN group: Up to 12 weeks","effectByArm":[{"arm":"PRN (2-8) Group","deltaMin":664,"sd":null},{"arm":"PRN (9-14) Group","deltaMin":315,"sd":null},{"arm":"Scheduled EOD + PRN Group","deltaMin":109,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":98,"countries":["United States"]},"refs":{"pmids":["40629887","39520634","38985436","38764606","38659334","35038983","34455556","31932515"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":1033},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis"]}}